US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

REIN THERAPEUTICS INC

0.8180

+0.02443.07%

Post-market: 0.84430.0263+3.22%19:46 EDT

Volume:583.53K

Turnover:476.37K

Market Cap:69.97M

PE:-0.49

High:0.8550

Open:0.8000

Low:0.7707

Close:0.7936

52wk High:2.18

52wk Low:0.6940

Shares:85.54M

Float Shares:61.08M

Volume Ratio:0.75

T/O Rate:0.96%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6800

EPS(LYR):-1.9600

ROE:-96.42%

ROA:-21.02%

PB:6.86

PE(LYR):-0.42

Loading ...

Overview Company News Filings

Rein Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $8 From $10

THOMSON REUTERS

Rein Therapeutics director Josef H. von Rickenbach acquires $49,525 of common shares

Rein Therapeutics announces annual shareholder meeting

BRIEF-Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering

Rein Therapeutics closes $57.5 million follow-on common stock offering

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

THOMSON REUTERS

Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Rein Therapeutics Q1 FY26 net loss widens 6.13% to $5.84 million

Rein Therapeutics CEO Brian Windsor acquires 25,000 shares for $25,000

Rein Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview

Rein Therapeutics prices 50 million-share follow-on offering at $1 per share

Rein Therapeutics Inc - Prices Public Offering of 50 Mln Shares at $1.00 per Share for $50 Mln

THOMSON REUTERS

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

BRIEF-Rein Therapeutics Provides Clinical Trial Update For Phase 2 Renew Study Of Lti-03 In Idiopathic Pulmonary Fibrosis

Rein Therapeutics enrolls 8 patients in Phase 2 IPF trial for LTI-03

Rein Therapeutics Inc Files to Offer 30 Mln Shares - SEC Filing

THOMSON REUTERS

Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright

Rein Therapeutics FY2025 operating loss narrows 22.2% to $(50.6) million; net loss narrows 20.7% to $(50) million

Rein Therapeutics Doses First Patient in Phase 2 IPF Trial of LTI-03

Rein Therapeutics enters $2.875 million promissory note financing deal

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/RNTX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RNTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNTX\",,,,,undefined,":{"symbol":"RNTX","market":"US","secType":"STK","nameCN":"REIN THERAPEUTICS INC","latestPrice":0.818,"timestamp":1787342400000,"preClose":0.7936,"halted":0,"volume":583528,"hourTrading":{"tag":"盘后","latestPrice":0.844335,"preClose":0.818,"latestTime":"19:46 EDT","volume":7545,"amount":6175.739155,"timestamp":1787356011807,"change":0.026335,"changeRate":0.032194,"amplitude":0.077628},"delay":0,"changeRate":0.030745967741935457,"floatShares":61080100,"shares":85539032,"eps":-1.68,"marketStatus":"Market Closed","change":0.0244,"latestTime":"08-21 16:00:00 EDT","open":0.8,"high":0.855,"low":0.77065,"amount":476368.0136116,"amplitude":0.106288,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.68,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1498708800000,"exchange":"NASDAQ","adjPreClose":0.7936,"preHourTrading":{"tag":"盘前","latestPrice":0.81,"preClose":0.7936,"latestTime":"09:16 EDT","volume":3748,"amount":3020.7776214,"timestamp":1787318177272,"change":0.0164,"changeRate":0.020665,"amplitude":0.035534},"postHourTrading":{"tag":"盘后","latestPrice":0.844335,"preClose":0.818,"latestTime":"19:46 EDT","volume":7545,"amount":6175.739155,"timestamp":1787356011807,"change":0.026335,"changeRate":0.032194,"amplitude":0.077628},"volumeRatio":0.7519483352709723},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNTX\",,,,,undefined,":{"symbol":"RNTX","floatShares":61080100,"roa":"-21.02%","roe":"-96.42%","lyrEps":-1.959999,"volumeRatio":0.7519483352709723,"shares":85539032,"dividePrice":0,"high":0.855,"amplitude":0.106288,"preClose":0.7936,"low":0.77065,"week52Low":0.694,"pbRate":"6.86","week52High":2.18,"institutionHeld":0,"latestPrice":0.818,"eps":-1.68,"divideRate":0,"volume":583528,"delay":0,"ttmEps":-1.68,"open":0.8,"prevYearClose":1.16,"prevWeekClose":0.806,"prevMonthClose":0.7374,"prevQuarterClose":1.04,"fiveDayClose":0.806,"twentyDayClose":0.7913,"sixtyDayClose":1.06},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RNTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"RNTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.27,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-0.1},{"market":"US","date":"2026-05-15","symbol":"RNTX","fiscalQuarterEnding":"2026/03","expectedEps":-0.49,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-0.19},{"market":"US","date":"2026-03-26","symbol":"RNTX","fiscalQuarterEnding":"2025/12","expectedEps":-0.24,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.36},{"market":"US","date":"2025-11-14","symbol":"RNTX","fiscalQuarterEnding":"2025/09","expectedEps":-0.24,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2025-08-14","symbol":"RNTX","fiscalQuarterEnding":"2025/06","expectedEps":-0.22,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.28}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RNTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RNTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.6667,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1784606400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RNTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RNTX","date":"2026-08-21","current":-0.486905,"percent":0.279302,"low":-2.05691,"twenty":-1.502634,"median":-0.637436,"eighty":-0.517826,"high":-0.401342,"avg":-0.920644,"sd":0.504006,"marketCap":67883775},"quantilePoints":[{"date":"2025-01-17","current":-1.459659,"twenty":-1.48337,"median":-1.467068,"eighty":-1.447804,"marketCap":42681903},{"date":"2025-01-24","current":-1.630077,"twenty":-1.576729,"median":-1.478183,"eighty":-1.446322,"marketCap":47665070},{"date":"2025-01-31","current":-1.467069,"twenty":-1.741219,"median":-1.496707,"eighty":-1.462623,"marketCap":42898563},{"date":"2025-02-07","current":-1.704171,"twenty":-1.704171,"median":-1.526344,"eighty":-1.459659,"marketCap":49831664},{"date":"2025-02-14","current":-1.741218,"twenty":-1.704171,"median":-1.578211,"eighty":-1.462623,"marketCap":50914961},{"date":"2025-02-21","current":-1.98573,"twenty":-1.794566,"median":-1.630077,"eighty":-1.468551,"marketCap":58064721},{"date":"2025-02-28","current":-1.533754,"twenty":-1.79753,"median":-1.630077,"eighty":-1.47596,"marketCap":44848497},{"date":"2025-03-07","current":-1.467069,"twenty":-1.753073,"median":-1.607848,"eighty":-1.468551,"marketCap":42898563},{"date":"2025-03-14","current":-1.496707,"twenty":-1.741218,"median":-1.552277,"eighty":-1.467069,"marketCap":43765200},{"date":"2025-03-21","current":-1.430022,"twenty":-1.733809,"median":-1.518935,"eighty":-1.461141,"marketCap":41815266},{"date":"2025-03-28","current":-1.311471,"twenty":-1.704171,"median":-1.507821,"eighty":-1.431504,"marketCap":38348715},{"date":"2025-04-04","current":-1.259605,"twenty":-1.704171,"median":-1.496707,"eighty":-1.416685,"marketCap":36832099},{"date":"2025-04-11","current":-0.545587,"twenty":-1.696762,"median":-1.481888,"eighty":-1.32629,"marketCap":34308123},{"date":"2025-04-17","current":-0.577063,"twenty":-1.667124,"median":-1.474478,"eighty":-1.296652,"marketCap":36287438},{"date":"2025-04-25","current":-0.640015,"twenty":-1.630077,"median":-1.467069,"eighty":-1.259605,"marketCap":40246068},{"date":"2025-05-02","current":-0.573565,"twenty":-1.630077,"median":-1.459659,"eighty":-0.64701,"marketCap":36067514},{"date":"2025-05-09","current":-0.601544,"twenty":-1.630077,"median":-1.437431,"eighty":-0.622528,"marketCap":37826905},{"date":"2025-05-16","current":-0.825375,"twenty":-1.622667,"median":-1.430022,"eighty":-0.622528,"marketCap":51902033},{"date":"2025-05-23","current":-0.696336,"twenty":-1.607848,"median":-1.415203,"eighty":-0.629523,"marketCap":42665230},{"date":"2025-05-30","current":-0.696336,"twenty":-1.584138,"median":-1.407793,"eighty":-0.629523,"marketCap":42665230},{"date":"2025-06-06","current":-0.705061,"twenty":-1.560428,"median":-1.311471,"eighty":-0.635119,"marketCap":43199785},{"date":"2025-06-13","current":-0.712292,"twenty":-1.550055,"median":-1.296652,"eighty":-0.639316,"marketCap":43642859},{"date":"2025-06-20","current":-0.592974,"twenty":-1.539682,"median":-1.259605,"eighty":-0.638616,"marketCap":36332127},{"date":"2025-06-27","current":-0.524276,"twenty":-1.524863,"median":-1.24849,"eighty":-0.622528,"marketCap":32122917},{"date":"2025-07-03","current":-0.54597,"twenty":-1.518935,"median":-0.809312,"eighty":-0.609134,"marketCap":33452141},{"date":"2025-07-11","current":-0.535123,"twenty":-1.515971,"median":-0.771713,"eighty":-0.598047,"marketCap":32787529},{"date":"2025-07-18","current":-0.506198,"twenty":-1.508562,"median":-0.726755,"eighty":-0.578462,"marketCap":31015230},{"date":"2025-07-25","current":-0.513429,"twenty":-1.504116,"median":-0.717873,"eighty":-0.562281,"marketCap":31458305},{"date":"2025-08-01","current":-0.421229,"twenty":-1.501152,"median":-0.708677,"eighty":-0.556817,"marketCap":25809102},{"date":"2025-08-08","current":-0.417509,"twenty":-1.496707,"median":-0.703515,"eighty":-0.543648,"marketCap":25581194},{"date":"2025-08-15","current":-0.434435,"twenty":-1.490779,"median":-0.698131,"eighty":-0.532953,"marketCap":26618269},{"date":"2025-08-22","current":-0.445213,"twenty":-1.481888,"median":-0.696336,"eighty":-0.524276,"marketCap":26334772},{"date":"2025-08-29","current":-0.445213,"twenty":-1.478924,"median":-0.689114,"eighty":-0.516321,"marketCap":26334772},{"date":"2025-09-05","current":-0.537801,"twenty":-1.474478,"median":-0.673872,"eighty":-0.514875,"marketCap":31811472},{"date":"2025-09-12","current":-0.425513,"twenty":-1.472996,"median":-0.650825,"eighty":-0.513429,"marketCap":25169516},{"date":"2025-09-19","current":-0.453092,"twenty":-1.467069,"median":-0.643512,"eighty":-0.506198,"marketCap":26800874},{"date":"2025-09-26","current":-0.470822,"twenty":-1.467069,"median":-0.629523,"eighty":-0.496939,"marketCap":27849604},{"date":"2025-10-03","current":-0.457032,"twenty":-1.465587,"median":-0.622528,"eighty":-0.470507,"marketCap":27033925},{"date":"2025-10-10","current":-0.539771,"twenty":-1.459659,"median":-0.615534,"eighty":-0.469167,"marketCap":31927997},{"date":"2025-10-17","current":-0.504312,"twenty":-1.455213,"median":-0.601544,"eighty":-0.470507,"marketCap":29830538},{"date":"2025-10-24","current":-0.496432,"twenty":-1.437431,"median":-0.598047,"eighty":-0.472004,"marketCap":29364436},{"date":"2025-10-31","current":-0.61069,"twenty":-1.435949,"median":-0.596299,"eighty":-0.477169,"marketCap":36122917},{"date":"2025-11-07","current":-0.61463,"twenty":-1.430022,"median":-0.598047,"eighty":-0.479267,"marketCap":36355968},{"date":"2025-11-14","current":-0.531891,"twenty":-1.430022,"median":-0.598047,"eighty":-0.480672,"marketCap":31461895},{"date":"2025-11-21","current":-0.616035,"twenty":-1.42854,"median":-0.59455,"eighty":-0.480672,"marketCap":36275207},{"date":"2025-11-28","current":-0.700851,"twenty":-1.422612,"median":-0.598047,"eighty":-0.480672,"marketCap":41269619},{"date":"2025-12-05","current":-0.620499,"twenty":-1.415203,"median":-0.603206,"eighty":-0.482843,"marketCap":36538070},{"date":"2025-12-12","current":-0.687459,"twenty":-1.415203,"median":-0.607107,"eighty":-0.492492,"marketCap":40481028},{"date":"2025-12-19","current":-0.575859,"twenty":-1.407793,"median":-0.606928,"eighty":-0.496432,"marketCap":33909432},{"date":"2025-12-26","current":-0.589251,"twenty":-1.390011,"median":-0.606928,"eighty":-0.496432,"marketCap":34698024},{"date":"2026-01-02","current":-0.517826,"twenty":-1.341109,"median":-0.603755,"eighty":-0.496432,"marketCap":30492203},{"date":"2026-01-09","current":-0.54461,"twenty":-1.311471,"median":-0.601544,"eighty":-0.497777,"marketCap":32069386},{"date":"2026-01-16","current":-0.517826,"twenty":-1.30258,"median":-0.596299,"eighty":-0.498849,"marketCap":30492203},{"date":"2026-01-23","current":-0.598179,"twenty":-1.296652,"median":-0.593762,"eighty":-0.499215,"marketCap":35223751},{"date":"2026-01-30","current":-0.638355,"twenty":-1.293688,"median":-0.598047,"eighty":-0.499741,"marketCap":37589526},{"date":"2026-02-06","current":-0.508898,"twenty":-1.277387,"median":-0.593762,"eighty":-0.500131,"marketCap":29966475},{"date":"2026-02-13","current":-0.52229,"twenty":-1.259605,"median":-0.589251,"eighty":-0.501948,"marketCap":30755066},{"date":"2026-02-20","current":-0.49997,"twenty":-1.259605,"median":-0.58056,"eighty":-0.49997,"marketCap":29440747},{"date":"2026-02-27","current":-0.535682,"twenty":-1.255159,"median":-0.578693,"eighty":-0.50005,"marketCap":31543658},{"date":"2026-03-06","current":-0.531218,"twenty":-1.154976,"median":-0.575859,"eighty":-0.50116,"marketCap":31280794},{"date":"2026-03-13","current":-0.571395,"twenty":-0.81895,"median":-0.571395,"eighty":-0.504312,"marketCap":33646568},{"date":"2026-03-20","current":-0.580323,"twenty":-0.79198,"median":-0.575859,"eighty":-0.504312,"marketCap":34172296},{"date":"2026-03-27","current":-0.566931,"twenty":-0.783866,"median":-0.57248,"eighty":-0.504336,"marketCap":33383705},{"date":"2026-04-02","current":-0.6803,"twenty":-0.771713,"median":-0.575859,"eighty":-0.504434,"marketCap":33927228},{"date":"2026-04-10","current":-0.860214,"twenty":-0.793249,"median":-0.580323,"eighty":-0.506198,"marketCap":42899718},{"date":"2026-04-17","current":-0.955793,"twenty":-0.871458,"median":-0.580323,"eighty":-0.506198,"marketCap":47666354},{"date":"2026-04-24","current":-1.034505,"twenty":-0.955793,"median":-0.58056,"eighty":-0.506198,"marketCap":51591818},{"date":"2026-05-01","current":-0.761823,"twenty":-0.933304,"median":-0.589251,"eighty":-0.508898,"marketCap":37992888},{"date":"2026-05-08","current":-1.830837,"twenty":-0.955793,"median":-0.589251,"eighty":-0.508898,"marketCap":91305667},{"date":"2026-05-15","current":-1.768244,"twenty":-1.034505,"median":-0.593762,"eighty":-0.508898,"marketCap":88184106},{"date":"2026-05-22","current":-1.771841,"twenty":-1.259605,"median":-0.598047,"eighty":-0.508898,"marketCap":88960593},{"date":"2026-05-29","current":-2.05691,"twenty":-1.290724,"median":-0.598179,"eighty":-0.508898,"marketCap":103273325},{"date":"2026-06-05","current":-1.890133,"twenty":-1.32629,"median":-0.602094,"eighty":-0.50963,"marketCap":94899812},{"date":"2026-06-12","current":-1.715203,"twenty":-1.416685,"median":-0.60675,"eighty":-0.511716,"marketCap":86116928},{"date":"2026-06-18","current":-1.602722,"twenty":-1.430022,"median":-0.607107,"eighty":-0.512192,"marketCap":80469458},{"date":"2026-06-26","current":-1.733363,"twenty":-1.459659,"median":-0.611131,"eighty":-0.512894,"marketCap":87028710},{"date":"2026-07-02","current":-1.812304,"twenty":-1.467069,"median":-0.615082,"eighty":-0.513362,"marketCap":90992173},{"date":"2026-07-10","current":-1.848995,"twenty":-1.481888,"median":-0.616035,"eighty":-0.513362,"marketCap":92834346},{"date":"2026-07-17","current":-1.597348,"twenty":-1.504116,"median":-0.61855,"eighty":-0.513362,"marketCap":80199645},{"date":"2026-07-24","current":-1.482643,"twenty":-1.518935,"median":-0.622528,"eighty":-0.513389,"marketCap":74440529},{"date":"2026-07-31","current":-1.423159,"twenty":-1.517453,"median":-0.62645,"eighty":-0.513429,"marketCap":71453976},{"date":"2026-08-07","current":-1.343362,"twenty":-1.510044,"median":-0.629957,"eighty":-0.513969,"marketCap":67447526},{"date":"2026-08-14","current":-1.341658,"twenty":-1.504116,"median":-0.633891,"eighty":-0.51647,"marketCap":67361987},{"date":"2026-08-21","current":-1.364196,"twenty":-1.502634,"median":-0.637436,"eighty":-0.517826,"marketCap":67883775}],"updateTime":1787524957370},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RNTX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640958555","title":"Rein Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $8 From $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2640958555","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640958555?lang=en_us&edition=fundamental","pubTime":"2026-06-01 18:01","pubTimestamp":1780308077,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nAZN4SZUDP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639612724","title":"Rein Therapeutics director Josef H. von Rickenbach acquires $49,525 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2639612724","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639612724?lang=en_us&edition=fundamental","pubTime":"2026-05-29 08:16","pubTimestamp":1780013800,"startTime":"0","endTime":"0","summary":"Rein Therapeutics director Josef H. von Rickenbach reported open-market purchases of common stock.Total acquired: 47,060 shares at weighted average prices of $1.04 to $1.07 per share.Directly owned stake rose to 62,514 shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL96Jhxr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Rein Therapeutics director Josef H. von Rickenbach acquires $49,525 of common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639619976","title":"Rein Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2639619976","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639619976?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:45","pubTimestamp":1780001156,"startTime":"0","endTime":"0","summary":"Rein Therapeutics will hold its 2026 annual shareholder meeting virtually on July 20, 2026.Shareholders will vote on electing two Class III directors to serve until the 2029 annual meeting.A proposal seeks to raise authorized common stock to 200,000,000 shares from 100,000,000.Items also include ratifying CBIZ CPAs as auditor for the year ending Dec. 31, 2026, plus an advisory vote on executive pay.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2026, and is solely responsible for the information contained ther","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL1jzL7X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636076340","title":"BRIEF-Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2636076340","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636076340?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:02","pubTimestamp":1779109356,"startTime":"0","endTime":"0","summary":"BRIEF-Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public OfferingMay 18 (Reuters) - Rein Therapeutics Inc RNTX.O:REIN THERAPEUTICS ANNOUNCES CLOSING OF $57.5 MILLION UNDERWRITTEN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V0SH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636738140","title":"Rein Therapeutics closes $57.5 million follow-on common stock offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2636738140","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636738140?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:03","pubTimestamp":1779105797,"startTime":"0","endTime":"0","summary":"Rein Therapeutics closed an underwritten public offering of 57,500,000 common shares at USD 1 per share, raising USD 57.5 million in gross proceeds.Deal size increased through the full exercise of the underwriters’ over-allotment option for an additional 7,500,000 shares.No warrants or other derivative securities were issued in the offering.Proceeds earmarked to fund the Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis through completion, support broader development work, working capital.Cash runway expected to extend into the first quarter of 2028 under the current operating plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief on May 18, 202","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL56SZLD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078277","title":"Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078277","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636078277?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:00","pubTimestamp":1779105646,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V0SH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635035352","title":"Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035352","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635035352?lang=en_us&edition=fundamental","pubTime":"2026-05-15 22:59","pubTimestamp":1778857179,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryRein Therapeutics Inc RNTX.OQ reported a quarterly adjusted loss of 19 cents per share for the quarter ended Marc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S1OF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635632081","title":"Rein Therapeutics Q1 FY26 net loss widens 6.13% to $5.84 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635632081","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635632081?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:57","pubTimestamp":1778846259,"startTime":"0","endTime":"0","summary":"Rein Therapeutics posted a net loss of $5.84 million for three months ended March 31, 2026, widening from $5.5 million a year earlier.Operating loss narrowed to $5.23 million as total operating expenses fell to $5.23 million from $5.61 million.Other expense swung to $608,000 from other income of $108,000, driven primarily by amortization of discount on notes payable tied to promissory notes.Cash and cash equivalents totaled $4.4 million at March 31, 2026; net proceeds of about $53.1 million from a May 2026 stock offering are expected to fund operations into first quarter 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic D","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL5LVW1d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635787865","title":"Rein Therapeutics CEO Brian Windsor acquires 25,000 shares for $25,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2635787865","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635787865?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:48","pubTimestamp":1778676482,"startTime":"0","endTime":"0","summary":"Rein Therapeutics President and Chief Executive Officer Brian Windsor reported purchase of 25,000 common shares at USD 1 per share, lifting direct holdings to 27,046 shares.Windsor also reported receipt of stock options for 150,000 shares with an exercise price of USD 1.17.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL2VDvGZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Rein Therapeutics CEO Brian Windsor acquires 25,000 shares for $25,000","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634628585","title":"Rein Therapeutics Inc  expected to post a loss of 49 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634628585","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634628585?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:28","pubTimestamp":1778498888,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc  expected to post a loss of49cents a share - Earnings Preview Rein Therapeutics Inc RNTX.OQ RNTX.O is expected to  show no change in quarterly revenue when it reports  results on","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O0ZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632969333","title":"Rein Therapeutics prices 50 million-share follow-on offering at $1 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2632969333","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632969333?lang=en_us&edition=fundamental","pubTime":"2026-05-01 08:00","pubTimestamp":1777593616,"startTime":"0","endTime":"0","summary":"Rein Therapeutics priced an underwritten public offering of 50 million common shares at USD 1 per share for gross proceeds of USD 50 million.Underwriters received a 45-day option to buy up to 7.5 million additional shares to cover over-allotments.Net proceeds earmarked to fund Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis through completion.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL3tN49v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","BK4585","BK4139","SG9999014039.USD","SG9999014005.SGD","LU2095319765.USD","BK4588","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","LU2210149790.SGD","LU0314104364.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014021.USD","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632336693","title":"Rein Therapeutics Inc - Prices Public Offering of 50 Mln Shares at $1.00 per Share for $50 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2632336693","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632336693?lang=en_us&edition=fundamental","pubTime":"2026-05-01 08:00","pubTimestamp":1777593600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nTUA6GY14C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632934256","title":"Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2632934256","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632934256?lang=en_us&edition=fundamental","pubTime":"2026-05-01 08:00","pubTimestamp":1777593600,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, April  30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. (\"Rein\" or the \"Company\") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-c","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/01/3285633/28652/en/Rein-Therapeutics-Announces-Pricing-of-50-Million-Underwritten-Public-Offering-of-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139","BK4007","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631191245","title":"BRIEF-Rein Therapeutics Provides Clinical Trial Update For Phase 2 Renew Study Of Lti-03 In Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2631191245","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631191245?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:18","pubTimestamp":1777465113,"startTime":"0","endTime":"0","summary":"BRIEF-Rein Therapeutics Provides Clinical Trial Update For Phase 2 Renew Study Of Lti-03 In Idiopathic Pulmonary FibrosisApril 29 (Reuters) - Rein Therapeutics Inc RNTX.O:REIN THERAPEUTICS PROVIDES CL","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41C0U4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631551623","title":"Rein Therapeutics enrolls 8 patients in Phase 2 IPF trial for LTI-03","url":"https://stock-news.laohu8.com/highlight/detail?id=2631551623","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631551623?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:03","pubTimestamp":1777464211,"startTime":"0","endTime":"0","summary":"Rein Therapeutics reported accelerated enrollment in Phase 2 RENEW study of LTI-03 for idiopathic pulmonary fibrosis.Study enrolled 8 patients to date, with 2 more expected this week.Enrollment started in March 2026, with additional patients being added on a regular basis.Trial sites are active in United States, Australia, Poland, with United Kingdom and Germany expected to open soon.No clinical results have been presented yet, with update focused on enrollment progress and site expansion.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL5V4WTb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","IE00BKPKM429.USD","BK4588","LU0314104364.USD","LU2095319765.USD","BK4585","BK4139","IE00BN0W2V16.EUR","LU2210150020.SGD","NDAQ","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4112","IE00BN0W2W23.USD","SG9999014039.USD","IE00BN0W2T93.GBP","SG9999014021.USD","IE00BGHQF748.EUR","RNTX","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631791531","title":"Rein Therapeutics Inc Files to Offer 30 Mln Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2631791531","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631791531?lang=en_us&edition=fundamental","pubTime":"2026-04-29 05:31","pubTimestamp":1777411910,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B0RQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624500191","title":"Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2624500191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624500191?lang=en_us&edition=fundamental","pubTime":"2026-04-02 23:00","pubTimestamp":1775142037,"startTime":"0","endTime":"0","summary":"H.C. Wainwright reiterates a Buy rating on Rein Therapeutics (RNTX) with a $10 price target after the company said it dosed the first patient in it...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rein-therapeutics-past-the-regulatory-uncertainty-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rein-therapeutics-past-the-regulatory-uncertainty-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RNTX","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622899156","title":"Rein Therapeutics FY2025 operating loss narrows 22.2% to $(50.6) million; net loss narrows 20.7% to $(50) million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622899156","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622899156?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:37","pubTimestamp":1774557475,"startTime":"0","endTime":"0","summary":"Rein published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025.Net loss was USD 49.9 million, compared with a USD 62.9 million net loss a year earlier.Total operating expenses were USD 50.6 million, down 22.24%, including R&D expense of USD 11.0 million  and G&A expense of USD 10.9 million .Impairment loss on intangible assets was USD 28.7 million, down 22.43%, after the company paused development activities related to LTI-01 for an indefinite period.Cash and cash equivalents were USD 3.2 million, and management said this, together with USD 4.3 million of proceeds received under promissory notes issued in January and February 2026, is expected to fund operations into the second quarter of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL9Y2Y1Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616340708","title":"Rein Therapeutics Doses First Patient in Phase 2 IPF Trial of LTI-03","url":"https://stock-news.laohu8.com/highlight/detail?id=2616340708","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616340708?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:02","pubTimestamp":1772542925,"startTime":"0","endTime":"0","summary":"Rein Therapeutics  announced it has dosed the first patient in its Phase 2 randomized, double-blind, placebo-controlled trial of LTI-03 for idiopathic pulmonary fibrosis following recent FDA clearance to resume the Phase 2 program. The study is expected to enroll about 120 patients across placebo, low-dose, and high-dose groups at sites in five countries and will monitor safety, tolerability, and lung function measures including forced vital capacity . Rein said enrollment is expected to continue through mid-2027, with interim data anticipated in the second half of 2026; the trial is currently active at five U.S. clinical sites and may expand to up to 50 sites.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. publi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL1SLSKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616733599","title":"Rein Therapeutics enters $2.875 million promissory note financing deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2616733599","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616733599?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:10","pubTimestamp":1772449807,"startTime":"0","endTime":"0","summary":"Rein Therapeutics Inc. entered into separate securities purchase agreements on Feb. 24 and 27, 2026 with three institutional investors for a private placement of unsecured promissory notes totaling $2.875 million in original principal amount, sold for $2.3 million reflecting a 20% original issue discount. The notes mature on the earlier of the company’s next qualifying securities financing raising at least $10 million in gross proceeds or June 30, 2026, and bear no interest other than the original issue discount.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL3jz1g3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":40,"code":"91000000","status":"200"}]}}